XCUR · Exicure
Exicure, Inc. does not have significant operations. Previously, it focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. The company has a co-development agreement with Adbiotech Co., Ltd. to explore combination therapies based on Burixafor (GPC-100) across multiple therapeutic areas. Exicure, Inc. was founded in 2011 and is headquartered in Redwood City, California.
Market Cap
6.939M
52 Wk Range
$0.78 - $9.48
Previous Close
$1.06
Open
$1.01
Volume
7,626
Day Range
$1.01 - $1.08
Enterprise Value
4.684M
Cash
1.717M
Avg Qtr Burn
-887K
Insider Ownership
41.47%
Institutional Own.
1.83%
Qtr Updated
Jun 30th 2026
